Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013502 · ClinicalTrials.gov registry record · Phase 1
Empagliflozin in Diuretic Refractory Ascites
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05013502: Completed Phase 1 study, sponsored by Stanford University.
NCT05013502 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013502, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Ascites is the most frequent complication of liver cirrhosis and results in increased morbidity and mortality but current medical management options are limited. Here, the investigators will conduct an interventional single-arm pilot clinical trial toevaluate the feasibility of empagliflozin in managing diuretic-resistant ascites in patients with decompensated cirrhosis. This single site, open label pilot study will enroll participants with decompensated cirrhosis at a single site. Participants will receive empagliflozin 10mg oral tablets once daily for 12 weeks with monitoring for safety and adverse events.
Interventions
- DRUG Empagliflozin 10 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05013502
The ClinicalTrials.gov registry entry for NCT05013502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Empagliflozin 10 MG is the first listed.
NCT05013502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05013502 about?
NCT05013502 is a clinical study titled "Empagliflozin in Diuretic Refractory Ascites". Ascites is the most frequent complication of liver cirrhosis and results in increased morbidity and mortality but current medical management options are limited. Here, the investigators will conduct an interventional single-arm pilot clinical trial toevaluate the feasibility of empagliflozin in mana...
What is the current status of trial NCT05013502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-11-15. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05013502?
The interventions under investigation include: Empagliflozin 10 MG (DRUG).
Who is sponsoring clinical trial NCT05013502?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.